Literature DB >> 1662634

Azithromycin levels in plasma and gastric tissue, juice and mucus.

J D Harrison1, J A Jones, D L Morris.   

Abstract

Azithromycin is the first member of a new class called the azalides. Its distribution in gastric tissues was studied in 27 patients (mean age 66 years) with proven gastric cancer due to be resected. Five groups of patients received a single 500 mg oral dose of azithromycin 24, 48, 72, 96 or 120 h pre-operatively. Samples of blood, gastric juice, mucus and gastric tissue were taken and azithromycin assayed by high performance liquid chromatography. There was an increase in the level of azithromycin in gastric juice up to the 73-96 h period reaching a median peak of 0.20 micrograms/ml. There were higher levels of azithromycin in gastric mucus (approximately double the maximum attained in gastric juice) at each of the time periods to 120 h after the dose of azithromycin. Much higher levels were seen in the gastric tissue (median peak of 4.6 micrograms/g), which were statistically significant compared with gastric juice for the first two time periods (24-48 h, p = 0.005; 49-72 h, p = 0.012). Concentrations seen in the gastric tissue specimens were between five- and 10-fold greater than those seen in gastric mucus, and approximately 20-fold greater than the levels seen in gastric juice at each of the time periods after dosing. It is concluded that remarkably high levels of azithromycin are found in gastric tissue within 24 h of a 500 mg oral dose and that these levels persist over a five-day period. There exists a significant concentration gradient from gastric tissue to gastric juice. Such levels may be advantageous in the therapy of Helicobacter pylori infections.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1662634     DOI: 10.1007/bf01975843

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  8 in total

1.  In vivo susceptibility of Campylobacter pylori.

Authors:  D Y Graham; P D Klein; A R Opekun; K E Smith; R R Polasani; D J Evans; D G Evans; L C Alpert; P A Michaletz; H H Yoshimura
Journal:  Am J Gastroenterol       Date:  1989-03       Impact factor: 10.864

2.  Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.

Authors:  J Retsema; A Girard; W Schelkly; M Manousos; M Anderson; G Bright; R Borovoy; L Brennan; R Mason
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

3.  The pharmacokinetics of azithromycin in human serum and tissues.

Authors:  G Foulds; R M Shepard; R B Johnson
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

4.  In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection.

Authors:  R P Gladue; G M Bright; R E Isaacson; M F Newborg
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

5.  Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides.

Authors:  G M Bright; A A Nagel; J Bordner; K A Desai; J N Dibrino; J Nowakowska; L Vincent; R M Watrous; F C Sciavolino; A R English
Journal:  J Antibiot (Tokyo)       Date:  1988-08       Impact factor: 2.649

6.  Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution.

Authors:  A E Girard; D Girard; A R English; T D Gootz; C R Cimochowski; J A Faiella; S L Haskell; J A Retsema
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

7.  Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa.

Authors:  C A McNulty; J C Dent; G A Ford; S P Wilkinson
Journal:  J Antimicrob Chemother       Date:  1988-11       Impact factor: 5.790

Review 8.  Campylobacter pylori--therapy review.

Authors:  A T Axon
Journal:  Scand J Gastroenterol Suppl       Date:  1989
  8 in total
  11 in total

1.  Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.

Authors:  Songmao Zheng; Peter Matzneller; Markus Zeitlinger; Stephan Schmidt
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

2.  Effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents.

Authors:  Y J Debets-Ossenkopp; F Namavar; D M MacLaren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

3.  The role of azithromycin in the treatment of Helicobacter pylori infection - a retrospective report.

Authors:  W Dohmen; R E Seelis
Journal:  Infection       Date:  1998 Jul-Aug       Impact factor: 3.553

4.  Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy.

Authors:  P Matzneller; S Krasniqi; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

5.  Azithromycin in a triple therapy for H.pylori eradication in active duodenal ulcer.

Authors:  Vladimir T Ivashkin; Tatiana L Lapina; Oksana Yu Bondarenko; Olga A Sklanskaya; Petr Ya Grigoriev; Yuri V Vasiliev; Emilia P Yakovenko; Pavel V Gulyaev; Valeri I Fedchenko
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

Review 6.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 7.  Azithromycin clinical pharmacokinetics.

Authors:  N J Lalak; D L Morris
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

8.  Measurement of tissue azithromycin levels in self-collected vaginal swabs post treatment using liquid chromatography and tandem mass spectrometry (LC-MS/MS).

Authors:  Lenka A Vodstrcil; Thusitha W T Rupasinghe; Fabian Y S Kong; Dedreia Tull; Karen Worthington; Marcus Y Chen; Wilhelmina M Huston; Peter Timms; Malcolm J McConville; Christopher K Fairley; Catriona S Bradshaw; Sepehr N Tabrizi; Jane S Hocking
Journal:  PLoS One       Date:  2017-05-12       Impact factor: 3.240

9.  A Robust Liquid Chromatographic Method for Confirmation of Drug Stability of Azithromycin in Bulk Samples, Tablets and Suspensions.

Authors:  Alex O Okaru; Kennedy O Abuga; Franco N Kamau; Stanley N Ndwigah; Dirk W Lachenmeier
Journal:  Pharmaceutics       Date:  2017-02-24       Impact factor: 6.321

10.  Higher organism load associated with failure of azithromycin to treat rectal chlamydia.

Authors:  F Y S Kong; S N Tabrizi; C K Fairley; S Phillips; G Fehler; M Law; L A Vodstrcil; M Chen; C S Bradshaw; J S Hocking
Journal:  Epidemiol Infect       Date:  2016-05-16       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.